Harnessing Human CD1d Restricted T Cells for Tumor Immunity: Progress and Challenges

Overview

Journal Front Biosci (Landmark Ed)

Specialty Biology

Date 2009 Mar 11

PMID 19273100

Citations 16

Authors

Madhav V Dhodapkar

Affiliations

Soon will be listed here.

Abstract

Glycolipid reactive CD1d restricted natural killer T (NKT) cells represent a distinct population of T cells implicated in the regulation of immune responses in a broad range of diseases including cancer. Several studies have demonstrated the capacity of NKT cells bearing an invariant T cell receptor (iNKT cells) to recruit both innate and adaptive anti-tumor immunity and mediate tumor rejection in mice. Early phase clinical studies in humans have demonstrated the capacity of dendritic cells (DCs) to mediate expansion of NKT cells in vivo. However several challenges need to be overcome in order to effectively harness the properties of these cells in the clinic.

Citing Articles

Identification of Functional Immune Biomarkers in Breast Cancer Patients.

Derakhshandeh R, Zhu Y, Li J, Hester D, Younis R, Koka R Int J Mol Sci. 2024; 25(22).

PMID: 39596374 PMC: 11595306. DOI: 10.3390/ijms252212309.

CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.

Tian G, Courtney A, Jena B, Heczey A, Liu D, Marinova E J Clin Invest. 2016; 126(6):2341-55.

PMID: 27183388 PMC: 4887157. DOI: 10.1172/JCI83476.

Improving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells.

Venkataswamy M, Ng T, Kharkwal S, Carreno L, Johnson A, Kunnath-Velayudhan S PLoS One. 2014; 9(9):e108383.

PMID: 25255287 PMC: 4177913. DOI: 10.1371/journal.pone.0108383.

Natural killer T cells: drivers or passengers in preventing human disease?.

Berzins S, Ritchie D Nat Rev Immunol. 2014; 14(9):640-6.

PMID: 25103356 DOI: 10.1038/nri3725.

CD1d levels in peripheral blood of patients with acute myeloid leukemia and acute lymphoblastic leukemia.

Guo W, Dong A, Xing C, Lin X, Pan X, Lin Y Oncol Lett. 2014; 8(2):825-830.

PMID: 25009659 PMC: 4081415. DOI: 10.3892/ol.2014.2208.

References

Kenna T, Golden-Mason L, Porcelli S, Koezuka Y, Hegarty J, OFarrelly C . NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J Immunol. 2003; 171(4):1775-9. DOI: 10.4049/jimmunol.171.4.1775. View

Osman Y, Kawamura T, Naito T, Takeda K, Van Kaer L, Okumura K . Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide. Eur J Immunol. 2000; 30(7):1919-28. DOI: 10.1002/1521-4141(200007)30:7<1919::AID-IMMU1919>3.0.CO;2-3. View

Uldrich A, Crowe N, Kyparissoudis K, Pellicci D, Zhan Y, Lew A . NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J Immunol. 2005; 175(5):3092-3101. PMC: 1360163. DOI: 10.4049/jimmunol.175.5.3092. View

Chang D, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer S . Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006; 108(2):618-21. PMC: 1895497. DOI: 10.1182/blood-2005-10-4184. View

Kojo S, Seino K, Harada M, Watarai H, Wakao H, Uchida T . Induction of regulatory properties in dendritic cells by Valpha14 NKT cells. J Immunol. 2005; 175(6):3648-55. DOI: 10.4049/jimmunol.175.6.3648. View

Eberl G, MacDonald H . Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur J Immunol. 2000; 30(4):985-92. DOI: 10.1002/(SICI)1521-4141(200004)30:4<985::AID-IMMU985>3.0.CO;2-E. View

Hermans I, Silk J, Gileadi U, Masri S, Shepherd D, Farrand K . Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells. J Immunol. 2007; 178(5):2721-9. DOI: 10.4049/jimmunol.178.5.2721. View

Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y . KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res. 1995; 7(10-11):529-34. View

Haraguchi K, Takahashi T, Matsumoto A, Asai T, Kanda Y, Kurokawa M . Host-residual invariant NK T cells attenuate graft-versus-host immunity. J Immunol. 2005; 175(2):1320-8. DOI: 10.4049/jimmunol.175.2.1320. View

10.

Chang D, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M . Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med. 2005; 201(9):1503-17. PMC: 1389847. DOI: 10.1084/jem.20042592. View

11.

Gadola S, Dulphy N, Salio M, Cerundolo V . Valpha24-JalphaQ-independent, CD1d-restricted recognition of alpha-galactosylceramide by human CD4(+) and CD8alphabeta(+) T lymphocytes. J Immunol. 2002; 168(11):5514-20. DOI: 10.4049/jimmunol.168.11.5514. View

12.

Shimizu K, Goto A, Fukui M, Taniguchi M, Fujii S . Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. J Immunol. 2007; 178(5):2853-61. DOI: 10.4049/jimmunol.178.5.2853. View

13.

Wu D, Segal N, Sidobre S, Kronenberg M, Chapman P . Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med. 2003; 198(1):173-81. PMC: 2196074. DOI: 10.1084/jem.20030446. View

14.

Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M . A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res. 2005; 11(5):1910-7. DOI: 10.1158/1078-0432.CCR-04-1453. View

15.

Brigl M, Brenner M . CD1: antigen presentation and T cell function. Annu Rev Immunol. 2004; 22:817-90. DOI: 10.1146/annurev.immunol.22.012703.104608. View

16.

Stober D, Jomantaite I, Schirmbeck R, Reimann J . NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo. J Immunol. 2003; 170(5):2540-8. DOI: 10.4049/jimmunol.170.5.2540. View

17.

Kawano T, Nakayama T, Kamada N, Kaneko Y, Harada M, Ogura N . Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res. 1999; 59(20):5102-5. View

18.

Hermans I, Silk J, Gileadi U, Salio M, Mathew B, Ritter G . NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol. 2003; 171(10):5140-7. DOI: 10.4049/jimmunol.171.10.5140. View

19.

Fujii S, Shimizu K, Klimek V, Geller M, Nimer S, Dhodapkar M . Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes. Br J Haematol. 2003; 122(4):617-22. DOI: 10.1046/j.1365-2141.2003.04465.x. View

20.

Smyth M, Thia K, Street S, Cretney E, Trapani J, Taniguchi M . Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med. 2000; 191(4):661-8. PMC: 2195840. DOI: 10.1084/jem.191.4.661. View